ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO574

Sarcopenia Prevalence According to Short Daily and Conventional Hemodialysis Regimens: Preliminary Findings from the SARC-HD Study

Session Information

Category: Dialysis

  • 801 Dialysis: Hemodialysis and Frequent Dialysis


  • Ribeiro, Heitor S., Universidade de Brasilia, Brasilia, Brazil
  • Duarte, Marvery P., Universidade de Brasilia, Brasilia, Brazil
  • Vieira, Fábio Augusto Silva, Universidade de Brasilia, Brasilia, Brazil
  • Baião, Victor Mota, Universidade de Brasilia, Brasilia, Brazil
  • Varela, Priscila Maria, IdealCor, Brasília, Brazil
  • Monteiro, Jacqueline Faria de Santana, DaVita Brasil Participacoes e Servicos de Nefrologia Ltda, Rio de Janeiro, Rio de Janeiro, Brazil
  • Inda-Filho, Antonio Jose, Centro Universitario ICESP, Brasilia, DF, Brazil
  • Nobrega, Otavio, Universidade de Brasilia, Brasilia, Brazil

Sarcopenia is a skeletal muscle disorder characterized by the loss of muscle strength, muscle mass, and performance, and is highly prevalent in patients undergoing hemodialysis (HD). Despite the increasing interest and clinical recognition, there is little understanding of how sarcopenia evolves across users of different modalities of HD regimens. Therefore, we investigated the prevalence of sarcopenia according to short daily and conventional hemodialysis regimens.


This cross-sectional multicenter study included eight dialysis units in Brasilia, Brazil, and enrolled adult patients undergoing HD for ≥3 months. Muscle strength was evaluated by handgrip strength and five-time sit-to-stand test. Calf circumference was used to estimate muscle mass, and physical performance through the 4-m gait speed test. Stages of sarcopenia were defined according to the revised European Working Group on Sarcopenia in Older People. Patients were stratified according to the hemodialysis regimen, short-daily (5 to 6 sessions/week, duration ~2h30) and conventional (3 sessions/week, duration ~4h).


The study enrolled 258 patients (66% male, 58.3 ± 0.9 years), 45% on conventional HD. The overall prevalence of probable sarcopenia (low muscle strength), sarcopenia, and severe sarcopenia was 26.7%, 26.7%, and 8.5%, respectively. No significant differences were found in the prevalence of sarcopenia, low muscle mass, and low physical performance between patients undergoing short daily and conventional HD (30.3% vs. 22.4%; P > 0.05). The low muscle strength was significantly higher in patients undergoing short daily compared to those receiving conventional HD (19.0% vs. 32.0%; P = 0.024).


Our multicenter study revealed a high prevalence of sarcopenia; however no significant difference was observed in prevalence between different HD regimens. Nevertheless, patients on short daily regimens had a higher prevalence of low muscle strength. This highlights a potential association between the HD regimen and the primary manifestation of sarcopenia, precisely muscle strength.